Content of review 1, reviewed on May 31, 2021

  • OOverall statement: Cancer immunotherapy blocking immune checkpoints are of great interest to researchers. In this review article, Sibaud reported immune risks due to the use of checkpoint inhibitors in cancer treatment. A wide range of dermatologic manifestations can occur suggesting that cutaneous toxicities is a side effect of this kind of treatments. The author concludes that these results suggest that early recognition of these manifestations and adequate management are critical to prevent evolution and propagation of the lesions.

  • Abstract:  -The goal of the study is clear  -The title sums up well the outcome of this study  -The conclusions are clear and we can know a lot about the article without having to read the whole discussion section. 

  • Introduction:  -An adequate bibliographic review based on recent articles  -The statements in the context are important and have been justified by clear figures (low percentage of patients completely treated)  -The purpose of the study is important and clearly stated.  - The target population studied is well identified . 
    *The rest of the article:  - This paper does an excellent job counting all of the possible dermatological toxicities that might appear as a second effect of cancer immunotherapy.  - The parts of the article are well balanced. The scientific accuracy is guaranteed as the author have interpreted and presented the relevant results correctly. The manuscript's figures and tables are clear and easy to understand. The bibliography is based on a large majority of recent references dating less than five years.  -This systematic review is so important to the scientific community, as it summarizes the current knowledge in the toxicity occurring due to immune checkpoint blockade, a novelty treatment under continuous study, development and discovery.  -The extrapolations made by the author: Early recognition of the lesions are necessary to prevent their exacerbation without having to interrupt the immunotherapy

Source

    © 2021 the Reviewer.